AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00981435
Drug: Prednisolone 1%
RxNorm normalized name: GENTAMICIN 0.3/PREDNISOLONE 1% OPH SUSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 1% to lasered eye 4 times/day for 4.5 days
Trial: NCT00981435
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac 0.5% to lasered eye 4 times/day for 4.5 days
Trial: NCT00466505
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg po BID starting on day 1 and continuing until progressive disease, excessive toxicity or removal from study for other reasons listed in the protocol.
Trial: NCT03752905
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline control
Trial: NCT00002523
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002523
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00827489
Drug: HTC-867
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03563534
Drug: Glass Ionomer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Margins of cavitated lesion(s) will be excavated.The carious teeth will be isolated, kept dry, apply resin modified glass ionomer.
Trial: NCT00628810
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00628810
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02910778
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo once daily for 14 days (until study day 15). On study day 15, placebo in combination with a loading dose of 180 mg ticagrelor will be administered.
Trial: NCT01412437
Drug: sapropterin dihydrochloride
RxNorm normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 20 mg/kg for 4 months
Trial: NCT01412437
Drug: sapropterin dihydrochloride
RxNorm normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00831051
Drug: Q8003
RxNorm normalized name: POUCH,DRAINABLE,NEW IMAGE H#18003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One Q8003 (morphine sulfate and oxycodone HCl) 12mg/8mg IR Capsule q6h
Trial: NCT00831051
Drug: Q8003
RxNorm normalized name: POUCH,DRAINABLE,NEW IMAGE H#18003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One Q8003 (morphine sulfate and oxycodone HCl) 6mg/4mg IR Capsule q6h
Trial: NCT03659435
Drug: RID-TDS 9.5 mg/24 h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
Trial: NCT03659435
Drug: Exelon® 9.5 mg/24 h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
Trial: NCT00847613
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo tablets administered BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
Trial: NCT00847613
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets administered at 5 mg BID daily through the end of the study during the double-blind, active-extension period.
Trial: NCT00847613
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets administered at 10 mg BID daily through the end of the study during the double-blind, active-extension period.
Trial: NCT00040534
Drug: Farnesyl Protein Transferase Inhibitor
RxNorm normalized name: farnesyl acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00396578
Drug: aerosolized vancomycin or gentamicin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00561353
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules identical in appearance to TMC435 capsules taken orally (by mouth) once daily for 28 days.
Trial: NCT01273818
Drug: Gentamicin and cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 mg topically, intra-operative,single dose and intravenous 1000 mg cefazolin 1 hour before operation
Trial: NCT01273818
Drug: Gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 mg gentamicin application intraoperatively
Trial: NCT03180762
Drug: JNJ-64140284 0.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of JNJ-64140284 will be administered as an oral solution.
Trial: NCT03180762
Drug: JNJ-64140284 2.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg of JNJ-64140284 will be administered as an oral solution.
Trial: NCT03180762
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered.
Trial: NCT00772395
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given once weekly start on 2nd postoperative day for 26 weeks (6 months)
Trial: NCT04432428
Drug: Sufentanil Sublingual Tablet
RxNorm normalized name: SUFentanil Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: all patients will receive tablets for sublingual use, containing 15 microgram of sufentanil. The sufentanil tablets come in a cartridge (40 tablets) and are administered with a special patient-controlled device that uses thumb tag recognition.~max dose per hour : 3 tablets of 15µg sufentanil
Trial: NCT01815684
Drug: ASP3652
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01815684
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00640822
Drug: Calcipotriol plus hydrocortisone ointment vehicle
RxNorm normalized name: hydrocortisone Rectal Ointment [Hemorrodil Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily application for up to 8 weeks
Trial: NCT00640822
Drug: Calcipotriol plus hydrocortisone ointment
RxNorm normalized name: hydrocortisone Rectal Cream [Recort Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily application for up to 8 weeks
Trial: NCT03368235
Drug: AZD9567
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral OD SGRM administered as suspension
Trial: NCT03368235
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral capsules of 20 mg prednisolone administered OD for two weeks
Trial: NCT01697345
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03426046
Drug: Pulp Capping Agents
RxNorm normalized name: acai fruit pulp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biocompatible materials
Trial: NCT03520049
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04407234
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen administered orally.
Trial: NCT01515046
Drug: Gemcitabine with escalating ascorbic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1000 mg/m2 weekly for 3 weeks with one week off (this is 1 cycle)~Ascorbate dose is targeted to achieve plasma level of 350 mg/dL. Infusions are given twice weekly, each week of a cycle (4 weeks to a cycle)
Trial: NCT04025203
Drug: Ibuprofen Arginine
RxNorm normalized name: ibuprofen arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT04099732
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet
Trial: NCT04485884
Drug: IN-C005 dose A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One time dose of IN-C005 dose A taken orally.
Trial: NCT04485884
Drug: IN-C005 dose B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One time dose of IN-C005 dose B taken orally.
Trial: NCT04485884
Drug: IN-C005 dose C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One time dose of IN-C005 dose C taken orally.
Trial: NCT04485884
Drug: IN-C005 dose F
RxNorm normalized name: F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of IN-C005 dose F once daily for 7 days.
Trial: NCT01731093
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00504244
Drug: continuation of azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine 2 mg/kg
Trial: NCT00277017
Drug: 5-Flourouracil, Interferon-a, IL-2 and Thalidomide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive oral dosages of Thalidomide at 200mg/day to start, with dosage gradually increasing up to a max of 1200mg/day. This will be taken in combination with:5-fluorouracil, given by continuous IV infusion over 24 hours (Day 1) every week for 4 weeks.~Interferon-α, given subcutaneously on Day 1, 3 and 5 of every week for 4 weeks. Interleukin-2, given by continuous IV infusion Days 2-5, every week for 4 weeks.~Treatment will be followed by 2 weeks of rest then repeated.
Trial: NCT01762761
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03017508
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a sublingual tablet identical to the active drug will be given before performing an anxiety provoking speech task. Participants will then be clinically assessed every hour for three hours.
Trial: NCT03224468
Drug: Medical Marijuana
RxNorm normalized name: Picea mariana resin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group can choose when, where, and how much medical marijuana to use.
Trial: NCT01381107
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual administration once daily for 7 consecutive days.
Trial: NCT00618956
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00705900
Drug: LCD
RxNorm normalized name: MGlcDAG (1->2) glucosyltransferase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 applications / day for 12 weeks
Trial: NCT03296189
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mls normal saline
Trial: NCT01038921
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 8 mg dose of Melatonin
Trial: NCT01038921
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01465334
Drug: High-Dose Methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00422539
Drug: 70% trichloroacetic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01918332
Drug: Rosuvastatin 20mg
RxNorm normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01918332
Drug: Rosuvastatin 20mg placebo
RxNorm normalized name: rosuvastatin 20 MG
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00536952
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 2.5 mL ampules (2.5 mg) will be nebulized and inhaled once daily using a recommended nebulizer
Trial: NCT00946907
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3000mg/day of aspirin during the 4th first days and 2000mg/day of placebo during the 17th following days
Trial: NCT00843986
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premix bag
Trial: NCT03697239
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25, 37.5, 56.25 or 75 grams/m2
Trial: NCT03206658
Drug: Spironolactone 25 mg
RxNorm normalized name: spironolactone 25 MG
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A dose of 25 mg of spironolactone will be administered orally or through the nasogastric /nasoenteral tube to the patients every 24 hours, at 8-9 am.
Trial: NCT03206658
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The contents of a placebo capsule will be administered orally or through the nasogastric / nasoenteral tube to the patients every 24 hours, at 8-9 am.
Trial: NCT00509886
Drug: Drysol
RxNorm normalized name: Drysol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% aluminum chloride hexahydrate
Trial: NCT00509886
Drug: Drioff
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% aluminum acetate
Trial: NCT04680884
Drug: Experimental for steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg/day of IV methylprednisolone for three days. As of day 4, the daily dose will be tapered to 1 mg/kg/day until day 7, followed by 0,5 mg/kg/day from day 8 to day 14 + IV placebo of isavuconazole
Trial: NCT03951987
Drug: 4 ml CG5503
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml of the CG5503 infusion solution corresponding to 40 mg CG5503 (tapentadol hydrochloride).
Trial: NCT01284192
Drug: ASP3026
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT00825071
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml, intravenously
Trial: NCT04438655
Drug: Oral antibiotic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antibiotic drugs:~- Bimixin (Neomicin + Bacitracin tablet) 25000 UI + 2500 UI: h. 8-16-24 the day before surgery if the procedure takes place in the morning; h. 16-24-8 if the procedure takes place in the afternoon.
Trial: NCT02514538
Drug: Non- effervescent Paracetamol kern
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1g
Trial: NCT02514538
Drug: Effervescent paracetamol termalgin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g
Trial: NCT00181298
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dispensing initially 5 mg. Dose Increased by 5 mg weekly to 20 mg/d final dose by week 4
Trial: NCT02799381
Drug: Optimized antiparkinsonian treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose levels of prescribed antiparkinsonian medications were individually optimized to their maximum therapeutic effect.
Trial: NCT02799381
Drug: Levodopa-Carbidopa Intestinal Gel (LCIG)
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose levels were individually optimized.
Trial: NCT04079777
Drug: Clinical treatment
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid Resuscitation, Anti-infection
Trial: NCT02525172
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02638012
Drug: Floseal
RxNorm normalized name: Floseal Hemostatic Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine spray (2%) is then administered using 1-2 sprays in the affected nasal cavity via the nostril that is to have Floseal® applied. Once the bleeding has stopped following application of the Floseal® a 50 cc syringe with sterile saline will be used to irrigate the treated nasal cavity to remove any excess Floseal® product as per manufacturer recommendations. This is done with the patient's head tilted downwards at a 30 degree angle so that the irrigation and excess product is removed from the nasal cavity. Once the irrigation is complete, the nasal cavity is inspected for evidence of continued bleeding.
Trial: NCT01712360
Drug: NAFT500 (pediatric)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied to both feet and groin area
Trial: NCT01712360
Drug: NAFT600 (pediatric)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied to both feet only
Trial: NCT01712360
Drug: NAFT500 (adult)
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Applied to both feet and groin area
Trial: NCT01712360
Drug: NAFT600 (adult)
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Applied to both feet
Trial: NCT02574221
Drug: cavity protection toothpaste
RxNorm normalized name: Aquafresh Cavity Protection Toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.243% sodium fluoride toothpaste
Trial: NCT01568944
Drug: Oral Antibiotic and Oral Rinse
RxNorm normalized name: beclometasone and antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO Amoxicillin in 500 mg / Metronidazole 250 mg of each TID for 8 days plus 2 ounces of 0.12% chlorhexidine mouthrinse used BID
Trial: NCT01691118
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00101361
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive an identically appearing placebo capsule until full healing occurs or for 24 weeks, which ever comes first.
Trial: NCT02061995
Drug: PREOB® Intravenous Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient will undergo a single intravenous administration of PREOB®.
Trial: NCT02935738
Drug: Prednisolone treatment
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infertile men were treated with prednisolone tablet, which is an intermediate acting corticosteroid, po, for 21 days of their wife's menstrual cycles. Briefly, the prednisolone regimen was started with a dose of 5mg, tid, for two weeks followed by 5mg bid for five days. This was further tapered to one tablet of 5mg/day for two days. Patients were then given one week of rest from the treatment, before this prednisolone regimen was repeated for another two cycles.
Trial: NCT03864276
Drug: inhalation (desflurane) group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthesia is induced and maintained with desflurane and sufentanil
Trial: NCT03864276
Drug: total intravenous (propofol) anesthesia
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthesia is induced and maintained with propofol and sufentanil
Trial: NCT01923064
Drug: Lauromacrogol
RxNorm normalized name: Lauromacrogol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: endoscopic injection of lauromacrogol + cyanoacrylate + lauromacrogol for gastric varices
Trial: NCT04146558
Drug: Individualized internal ayurvedic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All possible internal preparations will be administered for a period of 12 months.~All administered preparations with its dosage and duration will be documented All preparations will be subjected to lab test for clearing heavy metal and pesticide content before the administration
Trial: NCT03669133
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo daily
Trial: NCT02660944
Drug: RSLV-132
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RNase-Fc fusion protein
Trial: NCT02660944
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo
Trial: NCT03898934
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo for the same period
Trial: NCT01844076
Drug: Quinacrine and Capecitabine
RxNorm normalized name: quinacrine
DrugBank: Quinacrine (DB01103)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Phase I portion of the study will aim to determine the tolerability of both agents in combinations when used at established clinical doses. This portion of the study will more closely resemble a pilot study or feasibility study rather than a dose escalation.
Trial: NCT05839561
Drug: MTX as monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX in a single dose of 100 mg intravenously on day 0
Trial: NCT01400828
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (encapsulated) Tablets QD/14 days
Trial: NCT02286960
Drug: Steroid
RxNorm normalized name: Steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A short 4 day course is administered to the first group of patients with voice disorders before the initiation of voice therapy.
Trial: NCT01050777
Drug: Liposomal Paromomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal form of 10% Paromomycin
Trial: NCT01050777
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00520598
Drug: Comparator: V505 formulation 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml injection of V505 formulation 2 as 3 dose regimen at Day 1, Month 2 and Month 6.
Trial: NCT00520598
Drug: Comparator: V505 formulation 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml injection of V505 formulation 2 as 2 dose regimen at Day 1 and Month 6.
Trial: NCT03783910
Drug: GRT9906
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One prolonged-release tablet containing 40 mg of GRT9906
Trial: NCT03783910
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching GRT9906 tablets
Trial: NCT03348514
Drug: CPX-POM - 30 mg/m^2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPX-POM
Trial: NCT03348514
Drug: CPX-POM - 60 mg/m^2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPX-POM